Fly News Breaks for February 4, 2020
Feb 4, 2020 | 07:35 EDT
Goldman Sachs analyst Graig Suvannavejh raised his price target for Insmed to $46 from $33 and keeps a Buy rating on the shares following the "encouraging" results from the proof-of-concept Phase 2 INS007 study. The analyst increased his probability of success to 60% from 20%.
News For INSM From the Last 2 Days
There are no results for your query INSM